CSE | OTC | FSE

novamentis life science

The Nova Mission

We’re a Canadian-based biotechnology company and global leader in psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders. Our mission is to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder and fragile X syndrome.

 

Nova is the first company to achieve psilocybin orphan drug
designation
in both the U.S. and European Union for the treatment of
fragile X syndrome, the leading genetic cause of symptoms
related to autism spectrum disorder.

This provides us with financial benefits, market exclusivity,
research assistance and access to grants.

FDA EMA

 

Autism Spectrum Disorder and Fragile X Syndrome Observational Study

 

Learn More

Latest News

Nova Mentis Appoints Derek Ivany as Executive Chairman

Vancouver, British Columbia – January 18, 2023 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders is pleased to announce the appointment of Derek Ivany to the position of Executive Chairman. In this new role, Mr. Ivany’s mandate will include specific focus on corporate development outreach, mergers and ...

 

Nova Mentis Receives Health Canada Approval for First-of-its-Kind Psilocybin Clinical Trial

The human study will evaluate the Company’s proprietary psilocybin drug (NM-1001) in the treatment of Fragile X Syndrome

Vancouver, British Columbia – December 22, 2022 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and